Skip to main content

Peripheral Neuropathy

Neurology
0
Pipeline Programs
10
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

8 companies ranked by most advanced pipeline stage

CENTOGENE
CENTOGENEGermany - Rostock
1 program
Biomarker for Metachromatic Leukodystrophy (BioMeta) DiseaseN/A1 trial
Active Trials
NCT01536327Withdrawn0Est. Feb 2021
Young BioPharma
Young BioPharmaMA - Lowell
1 program
CalmareN/A1 trial
Active Trials
NCT04242797Completed39Est. Nov 2017
DyAnsys
DyAnsysCA - San Mateo
1 program
First Relief TreatmentN/A1 trial
Active Trials
NCT03540446Unknown66Est. Oct 2018
Abbott
AbbottABBOTT PARK, IL
1 program
Implantation with the commercially available Axium neurostimulatorN/A1 trial
Active Trials
NCT02349646Terminated33Est. Oct 2016
BlueWind Medical
BlueWind MedicalIsrael - Herzliya
1 program
The Reprieve SystemN/A1 trial
Active Trials
NCT02062398Completed13Est. Dec 2015
Genentech
GenentechCA - Oceanside
1 program
RituxanPHASE_21 trial
Active Trials
WinSanTor
WinSanTorCA - San Diego
1 program
WST-057PHASE_21 trial
Active Trials
NCT04005287Completed58Est. Dec 2021
Eisai
EisaiChina - Liaoning
1 program
Mecobalamin IV InjectionPHASE_41 trial
Active Trials
NCT01192113Completed1,072Est. May 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiMecobalamin IV Injection
WinSanTorWST-057
CENTOGENEBiomarker for Metachromatic Leukodystrophy (BioMeta) Disease
DyAnsysFirst Relief Treatment
Young BioPharmaCalmare
BlueWind MedicalThe Reprieve System
AbbottImplantation with the commercially available Axium neurostimulator

Clinical Trials (8)

Total enrollment: 1,281 patients across 8 trials

NCT01192113EisaiMecobalamin IV Injection

Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)

Start: Apr 2010Est. completion: May 20111,072 patients
Phase 4Completed

A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies

Phase 2Unknown

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

Start: Oct 2019Est. completion: Dec 202158 patients
Phase 2Completed
NCT01536327CENTOGENEBiomarker for Metachromatic Leukodystrophy (BioMeta) Disease

Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease

Start: Aug 2018Est. completion: Feb 20210
N/AWithdrawn
NCT03540446DyAnsysFirst Relief Treatment

First Relief Treatment for Peripheral Neuropathy

Start: Apr 2018Est. completion: Oct 201866 patients
N/AUnknown

Central Mechanisms of Calmare: an fMRI Trial

Start: Aug 2015Est. completion: Nov 201739 patients
N/ACompleted
NCT02062398BlueWind MedicalThe Reprieve System

BlueWind Medical Reprieve System for the Treatment of PNP

Start: May 2014Est. completion: Dec 201513 patients
N/ACompleted
NCT02349646AbbottImplantation with the commercially available Axium neurostimulator

A Post Market Cohort With the Spinal Modulation Neurostimulator System in Peripheral Neuropathy

Start: Apr 2013Est. completion: Oct 201633 patients
N/ATerminated

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.